Skip to main content
. Author manuscript; available in PMC: 2011 Feb 2.
Published in final edited form as: Clin Immunol. 2009 Mar 19;131(3):410–414. doi: 10.1016/j.clim.2009.01.016

Table 1.

CD38 and HLADR Expression on T cells in HIV-infected and uninfected Ugandan children.

Surface marker expression* HIV(+) ART-naïve (n = 199) HIV(+) ART ≥ 24 weeks§ (n = 57) HIV (−) (n = 30) pa pb pc
CD8−
CD3+CD8− CD38+ HLADR+ 13 (10–17) 10 (6–14) 5 (4–6) 0.005 < 0.001 < 0.001
CD3+CD8− CD38+ HLADR− 76 (68–81) 76 (68–80) 78 (72–80) 0.80 0.32 0.25
CD3+CD8− CD38− HLADR+ 2 (1–2) 2 (1–2) 2 (1–2) 0.25 0.25 0.94
CD8
CD3+CD8+ CD38+ HLADR+ 45 (34–54) 30 (21–40) 18 (13–21) < 0.001 < 0.001 < 0.001
CD3+CD8+ CD38+ HLADR− 50 (40–58) 62 (47–66) 66 (62–72) < 0.001 < 0.001 0.004
CD3+CD8+ CD38− HLADR+ 1 (1–3) 2 (1–4) 3 (2–6) 0.003 < 0.001 0.08
*

Percent of cells expressing, median (25th–75th%’ile);

§

median: 37.9 week (32.0–60.1).

p: p-value for Wilcoxon two-sample test;

a

HIV(+) ART-naïve vs. ART ≥ 24 weeks;

b

HIV(+) ART-naïve vs. HIV (−);

c

HIV(+) ART ≥ 24 weeks vs. HIV (−).